Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy Wolfe Research

Regeneron Pharmaceuticals Inc.
Start price
€718.60
16.11.24 / 50%
Target price
-
16.11.25
Performance (%)
-16.25%
End price
€601.80
17.11.25
Summary
This prediction ended on 17.11.25 with a price of €601.80. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -16.25%. Dividends of €2.60 are taken into consideration when calculating the performance. Wolfe_Research has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

AI-generated
Performance without dividends (%)
Name 1w 1m 1y
Regeneron Pharmaceuticals Inc. 2.374% 2.374% 39.972%
iShares Core DAX® 0.437% 5.897% 8.047%
iShares Nasdaq 100 1.057% 0.920% 28.466%
iShares Nikkei 225® 1.769% 1.228% 47.574%
iShares S&P 500 0.368% 1.920% 23.200%

Comments by Wolfe_Research for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Ratings data for REGN provided by MarketBeat

Wolfe Research 
0
Report Share
16.11.24 Buy -16.25%
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) -16.25%
Target price
Change
Ends at 16.11.25

Die von Wolfe_Research gewählte maximale Laufzeit wurde überschritten

Wolfe Research 
0
Report Share
17.11.25

Stopped prediction by Wolfe_Research for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€740.40
15.11.24
€1,088.8
15.11.25
-18.72%
16.11.25

Wolfe Research 
15.11.24 50%